Epigenomics' Q3 Revenues Fall 29 Percent; PMA Submission Targeted for Epi proColon 2.0 | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German cancer molecular diagnostics firm Epigenomics today reported revenues in the third quarter fell 29 percent year over year while its net loss increased by 60 percent.

For the three months ended Sept. 30, revenues totaled €257,000 ($349,000), compared to €363,000 ($493,000) a year ago, while its net loss rose to €4.8 million from €3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.